A Phase 3 interventional study of Glepaglutide and Placebo in Short Bowel Syndrome, sponsored by Zealand Pharma. Recruiting at 33 sites in 14 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Zealand Pharma · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Short Bowel Syndrome with a site in United States — 11 open to participants now, 15 under way, 4 of them phase 3. Short Bowel Syndrome · United States.
Among the 80 studies in Short Bowel Syndrome with a site in United States, this one is the 11th largest by planned enrollment of the 66 interventional ones that give a count, is one of 2 that started in 2026, is one of 20 in phase 3, reaches primary completion later than 9 of the 14 other live ones, and was the 78th registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →11 of the 80 studies in Short Bowel Syndrome with a site in United States are open now. Recruiting first, the newest first:
VectivBio AG · Sites in United States, Argentina, Australia and 19 more countries
Ages 18+
Eclipse Regenesis, Inc. · Sites in United States
Ages 3 mo–65 yrs
Children's Hospital of Philadelphia · Sites in United States
Ages 4 mo–18 yrs · Healthy volunteers
Hanmi Pharmaceutical Company Limited · Sites in United States, Belgium, Denmark and 5 more countries
Ages 18+
Boston Children's Hospital · Sites in United States, Canada
Ages 6 mo–25 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 23 · Phase 4 7
First in 1996; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 21 across 108 interventional studies indexed under Short Bowel Syndrome.
Median enrollment 23 across the 66 interventional studies, 143 across the 10 observational. Of the 52 that completed or were terminated, 29 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 80 have an industry lead sponsor. The 10 most frequent:
Zealand Pharma is the lead sponsor of 43 studies on the registry; 5 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.
Zealand Pharma has 7 studies filed under Short Bowel Syndrome — fewer than ten, so there is no comparison to draw.
4 of the studies in Short Bowel Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05018286Phase 3VectivBio AGOpen-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. | 2027-10-30 |
| NCT06240065University of Texas Southwestern Medical CenterSuccessful Fiber Food Introduction in Short Bowel Syndrome | 2027-04 |
| NCT03530852Boston Children's HospitalA 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB | 2027-06-30 |
| NCT05432648Children's Hospital of PhiladelphiaFiber Food Introduction in Pediatric Short Bowel Syndrome | 2027-08-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 80 studies in Short Bowel Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the present Phase 3 trial is to confirm the efficacy and safety of glepaglutide 10 mg twice weekly in a patient population with SBS-IF and generate additional long-term safety data.
Glepaglutide is the International Nonproprietary Name and United States Adopted Name (USAN) for ZP1848.
The trial is a phase 3, double-blind, randomized, parallel-group, placebo-controlled, multicenter trial to confirm the efficacy and safety of glepaglutide 10 mg twice weekly, followed by a long-term, open-label safety evaluation in patients with short bowel syndrome-intestinal failure (SBS-IF).
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Glepaglutide
Placebo for glepaglutide
Other: Placebo
Subcutaneous (SC) injections twice weekly
Also known as: ZP1848
SC injections twice weekly
Change in weekly Parenteral Support (PS) volume
Time frame: Baseline to Week 24
Proportion of participants achieving clinical response
Defined as achieving a reduction of at least 20% in weekly PS volume
Time frame: Baseline to Week 52
Proportion of participants achieving clinical response
Defined as achieving a reduction of at least 20% in weekly PS volume
Time frame: Baseline to Week 20 and Week 24
Proportion of participants with a reduction in days on PS ≥1 day/week
Time frame: Baseline to Week 52
Proportion of participants with a reduction in days on PS ≥1 day/week
Time frame: Baseline to Week 24
Proportion of participants with a reduction of 100% weekly PS volume (weaned-off)
Time frame: Baseline to Week 52
Proportion of participants with a reduction of 100% weekly PS volume (weaned-off)
Time frame: Baseline to Week 24
Proportion of participants achieving 'much better' Patient Global Impression of Change (PGIC) status
PGIC scoring categories are: 'Much better', 'A little better', 'No change', 'A little worse', and 'Much worse'
Time frame: Week 24
Change in weekly PS volume
Time frame: Baseline to Week 12
Change in weekly PS volume
Time frame: Baseline to Week 8
Incidence of Treatment Emergent Adverse Events (TEAEs)
Time frame: Baseline to Week 52
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Oct 2028, 32 months after the start.
Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's planned 32 months is below that.
Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glepaglutide